Compass Therapeutics, Inc. — Form 10-Q Summary
Business Context and Reporting Period
Compass Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company developing antibody-based therapeutics focused on angiogenesis and immune-oncology. The filing covers the three and nine months ended September 30, 2021. The company had no products approved for commercial sale and had never generated product revenue.
Key product candidates were CTX-009, CTX-471 and CTX-8371. The company completed its acquisition of TRIGR Therapeutics on June 25, 2021, obtaining CTX-009 and issuing 10.3 million common shares.
Financial Metrics
| Metric | Q3 2021 | Q3 2020 | 9M 2021 | 9M 2020 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development expense | $3.2 million | $3.7 million | $10.8 million | $10.5 million |
| General and administrative expense | $2.7 million | $5.3 million | $7.5 million | $9.4 million |
| In-process R&D expense | $0 | $0 | $50.6 million | $0 |
| Total operating expenses | $5.9 million | $9.0 million | $68.9 million | $19.9 million |
| Net loss | $6.0 million | $9.2 million | $69.2 million | $21.1 million |
| Net loss per share | $0.10 | $0.18 | $1.26 | $0.88 |
| Cash used in operating activities | Not provided | Not provided | $15.0 million | $20.2 million |
Margins are not meaningful because the company had no revenue. At September 30, 2021, cash and cash equivalents were $25.5 million, compared with $47.1 million at December 31, 2020. Total assets were $34.9 million and stockholders’ equity was $23.9 million. Accumulated deficit was $220.6 million.
Debt consisted of $3.75 million of principal outstanding under the Pacific Western Bank Credit Facility, presented net as $3.74 million current debt. The facility carried a 6.25% interest rate and was subject to a $6.0 million minimum cash covenant; the company reported compliance at September 30, 2021. Operating lease liabilities totaled $4.4 million.
Material Changes Versus Prior Comparable Period
- Nine-month net loss increased by $48.1 million, primarily because the TRIGR acquisition generated a $50.6 million noncash in-process R&D charge.
- Research and development expense increased modestly by $0.3 million for the nine-month period, while general and administrative expense declined by $1.9 million.
- Third-quarter net loss improved by $3.2 million, reflecting lower R&D and G&A expenses, including lower stock-based compensation and fewer reverse-merger-related costs.
- Operating cash use improved to $15.0 million from $20.2 million, but cash, cash equivalents and restricted cash declined by $21.6 million during the first nine months.
- Shares outstanding increased materially following the TRIGR acquisition; 61.8 million common shares were outstanding at September 30, 2021, versus 51.2 million at December 31, 2020.
Clinical Development, Outlook and Unusual Items
- CTX-009 clinical data were preliminary and derived largely from early-stage, open-label studies. Reported response rates included an 18.8% overall response rate at selected monotherapy doses and a 23.5% response rate in combination studies. In a Phase 2a biliary tract cancer study, five partial responses were observed among 17 evaluable patients, for a preliminary 29% response rate.
- Management planned to submit a U.S. IND for CTX-009 in the fourth quarter of 2021 and anticipated initiating a Phase 2 study in cholangiocarcinoma in the second quarter of 2022, subject to FDA clearance and manufacturing readiness.
- CTX-471 Phase 1b dose expansion was nearing completion, with completion expected in the first half of 2022 and a potential combination study planned thereafter.
- Manufacturing supply-chain delays at Fujifilm Diosynth Biotechnologies delayed the expected CTX-8371 IND submission to the second half of 2022.
- In November 2021, after the reporting date, the company completed a public offering and received approximately $117.3 million of net proceeds. On November 8, 2021, it repaid its remaining debt and terminated the Credit Facility.
- Management stated that cash resources, including the November offering proceeds, were expected to fund operating and capital requirements through the fourth quarter of 2024 under current plans. The company expects continuing losses and additional financing needs to complete development and commercialization.
- COVID-19 caused delays in patient enrollment and selected clinical-material supply, with potential further effects on trial timelines, costs and operations.
- Potential TRIGR earnouts totaled up to $9.0 million, but no provision was recorded for the $2.0 million regional-license earnout or the $5.0 million regulatory approval earnout because payment was not considered probable. A separate $2.0 million milestone could become payable to former TRIGR shareholders if CTX-009 receives IND approval in China.
Principal Risks and Contingencies
- The company has limited operating history, no commercial products and substantial accumulated losses; profitability may never be achieved.
- Clinical, regulatory and manufacturing outcomes are uncertain, and early-stage results may not predict later results.
- FDA agreement with proposed clinical designs, accelerated approval strategies and endpoints has not been obtained.
- The company relies on third parties for clinical research, manufacturing and supply, including suppliers affected by delays.
- Additional capital will be required; future equity financing could dilute existing stockholders, while debt or partnerships could impose restrictive terms or require relinquishing valuable rights.
- Risks include COVID-19 disruptions, overseas trial execution, adverse events, intellectual-property challenges, competition, reimbursement restrictions and integration risks associated with TRIGR.
Investor Verification Checklist
- Verify the November 2021 offering proceeds, final share count and resulting dilution.
- Confirm repayment of the Credit Facility and that no debt facilities remained after November 8, 2021.
- Assess whether the projected cash runway through the fourth quarter of 2024 remains supportable under updated clinical, manufacturing and spending plans.
- Validate CTX-009 response rates, durability, safety data and the number of evaluable patients in later-stage, controlled studies.
- Track FDA IND submissions, trial clearances and planned Phase 2 launches for CTX-009, CTX-471 and CTX-8371.
- Monitor manufacturing delays, clinical enrollment, potential TRIGR earnouts and milestone or royalty obligations under the ABL Bio and other license agreements.